Colorectal Cancer Clinical Trials in Boston

Showing 81-100 of 134 trials

Predicting Disease Progression and/or Recurrence in Cancer

NCT04776837

This is a prospective study addressing the challenge of predicting disease progression and/or recurrence in patients diagnosed with metastatic colorectal, pancreatobiliary, or esophagogastric cancer that are receiving anti-cancer therapy.

Patient Reported Outcome MeasuresColorectal CancerPancreatic Cancer+5 more

Massachusetts General Hospital200 participantsStarted May 2019

Boston, Massachusetts, United States

UNKNOWNPHASE2< 1 mile

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

NCT03668431

This research study is studying a combination of drugs as a possible treatment for metastatic colorectal cancer characterized by BRAF V600E mutation. The names of the study drugs involved in this study are: * Dabrafenib * Trametinib * PDR001

Metastatic Colorectal Cancer

Massachusetts General Hospital25 participantsStarted Oct 2018

Boston, Massachusetts, United States • Boston, Massachusetts, United States

COMPLETEDPHASE1< 1 mile

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

NCT02900664

The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.

Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

Novartis Pharmaceuticals283 participantsStarted Aug 2016

Baltimore, Maryland, United States • Boston, Massachusetts, United States • Nashville, Tennessee, United States +20 more locations

Predicting Disease Progression and/or Recurrence in Cancer

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Colorectal Cancer Trials in Other Cities

EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options

Patients' Preferences About Rescheduling Colonoscopies Delayed Due to COVID-19: Cross Sectional Study

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)

Improving Care After Chemotherapy

Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma

A Sustainable Approach to Increasing Cancer Screening

Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)

A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer

Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI

BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study

Adjuvant Aflibercept for Metastatic Colorectal Cancer

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

Comparison of Adenoma Detection Rate With ENDOCUFF VISION® vs. G-EYE®

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer

Other Conditions in Boston